Laura Karla Bozic

Dr. Laura Karla Bozic

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Jadranka Pavicic SaricJadranka Pavicic Saric
Jadranka Pavicic Saric
DLDinka Lulic
Dinka Lulic
DRDunja Rogic
Dunja Rogic
SJStipislav Jadrijevic
Stipislav Jadrijevic
DMDanko Mikulic
Danko Mikulic
ILIleana Lulic
Ileana Lulic
Virus-associated hepatocellular carcinoma (HCC) remains a major global health burden despite effective antiviral therapies. Chronic infection with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) promotes malignant transformation through overlapping pathways of fibrosis, immune dysregulation, and microenvironmental remodeling. YKL-40, a glycoprotein secreted by hepatic stellate cells, hepatocytes under stress, macrophages, and endothelial cells, has emerged as a marker that reflects stromal activation rather than direct hepatocyte injury. Its expression is reinforced by profibrotic and angiogenic circuits, and circulating concentrations correlate with advanced fibrosis, residual risk after viral suppression, and oncologic outcomes. This review synthesizes current evidence on YKL-40 across HBV, HCV, and HDV cohorts, with emphasis on its role in bridging molecular mechanisms to clinical applications. We examine its utility in non-invasive fibrosis assessment, longitudinal monitoring after antiviral therapy, and prognostic modeling in HCC. Particular attention is given to its potential in the liver transplant pathway, where YKL-40 may refine eligibility beyond morphology, inform bridging therapy response, and predict post-transplant recurrence or graft fibrosis. Remaining challenges include its lack of disease specificity, assay variability, and limited multicenter validation. Future integration of YKL-40 into multimarker, algorithm-based frameworks could enable risk-adaptive strategies that align surveillance and transplant decisions with the evolving biology of virus-associated liver disease.

30 May 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
NPNikola Prpić
Nikola Prpić
ILIleana Lulic
Ileana Lulic
LBLaura Karla Bozic
Laura Karla Bozic
MSMario Staresinic
Mario Staresinic
DLDinka Lulic
Dinka Lulic
Jadranka Pavicic SaricJadranka Pavicic Saric
Jadranka Pavicic Saric
Background: Anesthesia Information Management Systems (AIMSs) support perioperative documentation and clinical decision-making, but their real-world adoption remains heterogeneous and incompletely understood. Methods: This study combined a cross-sectional survey with a randomized crossover simulation study conducted at a tertiary care center following AIMS implementation. All anesthesiologists were invited to complete a structured questionnaire assessing satisfaction, usability, adoption, and use of decision-support functionalities. In the simulation study, participants entered standardized intraoperative data into both paper-based records and the electronic AIMS, with documentation time recorded. Survey data were analyzed descriptively with subgroup analyses, and documentation times were compared using the Wilcoxon signed-rank test. Results: A total of 27 anesthesiologists participated. Overall satisfaction and workflow integration were high, with 81.48% reporting that the system was easy to use and well-integrated into clinical practice. Electronic documentation was preferred across multiple domains, including time efficiency (92.59%) and accuracy (85.19%). In the simulation study, electronic documentation was significantly faster than paper-based documentation (median 540 vs. 1140 s; p = 0.0016). Adoption patterns demonstrated a bimodal distribution, with no association with technological literacy or engagement with educational materials. Decision-support features embedded within routine workflows were used more frequently than those requiring additional navigation. Conclusions: AIMS implementation was associated with high user satisfaction and improved documentation efficiency, but showed heterogeneous adoption and selective feature use. Effective integration appears to depend on workflow alignment rather than user characteristics alone.

28 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Jadranka Pavicic SaricJadranka Pavicic Saric
Jadranka Pavicic Saric
DLDinka Lulic
Dinka Lulic
DRDunja Rogic
Dunja Rogic
SJStipislav Jadrijevic
Stipislav Jadrijevic
DMDanko Mikulic
Danko Mikulic
ILIleana Lulic
Ileana Lulic
Virus-associated hepatocellular carcinoma (HCC) remains a major global health burden despite effective antiviral therapies. Chronic infection with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) promotes malignant transformation through overlapping pathways of fibrosis, immune dysregulation, and microenvironmental remodeling. YKL-40, a glycoprotein secreted by hepatic stellate cells, hepatocytes under stress, macrophages, and endothelial cells, has emerged as a marker that reflects stromal activation rather than direct hepatocyte injury. Its expression is reinforced by profibrotic and angiogenic circuits, and circulating concentrations correlate with advanced fibrosis, residual risk after viral suppression, and oncologic outcomes. This review synthesizes current evidence on YKL-40 across HBV, HCV, and HDV cohorts, with emphasis on its role in bridging molecular mechanisms to clinical applications. We examine its utility in non-invasive fibrosis assessment, longitudinal monitoring after antiviral therapy, and prognostic modeling in HCC. Particular attention is given to its potential in the liver transplant pathway, where YKL-40 may refine eligibility beyond morphology, inform bridging therapy response, and predict post-transplant recurrence or graft fibrosis. Remaining challenges include its lack of disease specificity, assay variability, and limited multicenter validation. Future integration of YKL-40 into multimarker, algorithm-based frameworks could enable risk-adaptive strategies that align surveillance and transplant decisions with the evolving biology of virus-associated liver disease.

13 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ILIleana Lulic
Ileana Lulic
IGIvan Gornik
Ivan Gornik
Jadranka Pavicic SaricJadranka Pavicic Saric
Jadranka Pavicic Saric
DRDunja Rogic
Dunja Rogic
AGAlberto Gallego
Alberto Gallego
DLDinka Lulic
Dinka Lulic
Objective: To map and characterize artificial intelligence (AI) applications in post-liver transplantation (LT) care, summarize comparative performance where available, and identify methodological and translational gaps. Methods: We conducted a scoping review in accordance with PRISMA-ScR. A comprehensive search of electronic databases was performed from inception through 1 April 2025. We included primary studies evaluating AI applications in the post-LT period (model development, validation, or implementation). Comparative studies were defined as those reporting head-to-head evaluation of at least two algorithmic models for the same task with quantitative performance metrics. Single-model studies were retained for evidence mapping but analyzed separately. Reviews and the other non-primary literature were included for contextual mapping. Results: The search yielded 3088 records. After deduplication, 2408 were screened, 191 full texts were assessed, and 65 studies were included. Of these, 52 reported primary outcome data. Clinical prediction studies (n = 43) focused on graft survival, rejection, fibrosis, oncologic recurrence, mortality, and composite outcomes. Operational studies (n = 3) evaluated early warning or bedside decision-support systems, and system-level studies (n = 6) examined benchmarking, donor–recipient matching, explainability, fairness, and cross-domain modeling. Most studies were retrospective and single-center, with internal validation commonly reported and external validation uncommon. Conclusions: AI research in post-LT care is expanding, with a predominant focus on clinical prediction. However, limited external validation, heterogeneous methods, and scarce real-world implementation constrain clinical readiness. Standardized evaluation and prospective integration are needed to determine whether AI tools can support decision-making and improve post-transplant outcomes.